ConductScience.org, home

Comparison · NCT05288348-c1b89bb7

DSUVIA (Sufentanil) vs Standard Care: Number of Participants With Headache

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. DSUVIA (Sufentanil) vs Standard Care: Number of Participants With Headache. Trial comparisons, record NCT05288348-c1b89bb7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05288348-c1b89bb7

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01320.002330.0708wilson
Risk in group 20.0270.007440.0933wilson
Risk difference, group 1 minus group 2-0.0139-0.0810.047newcombe hybrid score
Risk ratio, group 1 over group 20.4870.04515.26log
Odds ratio, group 1 over group 20.480.04265.41log
Number needed to treat, for one fewer participant with the outcome on DSUVIA (Sufentanil) than on Standard Care72.1from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: standard care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1DSUVIA (Sufentanil)
Subjects will receive a single dose of 30 micrograms DSUVIA (sufentanil) tablet utilizing a sublingual applicator~Sufentanil 30 MCG Sublingual Tablet: 30 microgram sublingual tablet administered using sublingual applicator
176OG000
Group 2Standard CareSubjects will receive standard care pain management~standard care pain treatment: standard care pain treatment given in Emergency Department274OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Headache
Description
Time frame
from administration to ED discharge or rescue narcotic administered, whichever comes first (up to 120 minutes)
Population

Source ClinicalTrials.gov

Trial

Title
DSUVIA Early Evaluation of Pain Trial
NCT number
NCT05288348
Phases
PHASE3
Conditions
Traumatic Injury
Interventions
Sufentanil 30 MCG Sublingual Tablet, standard care pain treatment
Lead sponsor
Frank Guyette
Results first posted
2025-04-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05288348-c1b89bb7